[2,3'-Bipyridine]-4-carboxamide, N-[1-(2-hydroxy-2-methylpropyl)-5-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]-4'-methoxy- manufacturers
- EGFR-IN-26
-
- $1520.00
-
2026-07-27
- CAS:2375470-64-5
- Purity:
- Supply Ability: 10g
|
| | [2,3'-Bipyridine]-4-carboxamide, N-[1-(2-hydroxy-2-methylpropyl)-5-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]-4'-methoxy- Basic information |
| | [2,3'-Bipyridine]-4-carboxamide, N-[1-(2-hydroxy-2-methylpropyl)-5-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]-4'-methoxy- Chemical Properties |
| density | 1.28±0.1 g/cm3(Predicted) | | pka | 11.90±0.43(Predicted) |
| | [2,3'-Bipyridine]-4-carboxamide, N-[1-(2-hydroxy-2-methylpropyl)-5-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]-4'-methoxy- Usage And Synthesis |
| Uses | EGFR-IN-26 is a EGFR inhibitor extracted from patent WO2019162323A1 compound I-028. EGFR-IN-26 can be used for the research of cancer[1]. | | References | [1] BOESE D, et, al. New benzimidazole compounds and derivatives as egfr inhibitors. WO2019162323A1. |
| | [2,3'-Bipyridine]-4-carboxamide, N-[1-(2-hydroxy-2-methylpropyl)-5-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]-4'-methoxy- Preparation Products And Raw materials |
|